Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

GRI Bio Q3 2026 Results: Net Loss of $1.51M, Loss Narrows

GRI Bio, Inc. reported a net loss of $5.15 million for the nine months ended September 30, 2026, a significant reduction from the $9.30 million loss in the prior year period, primarily due to lower research and development expenses. The company strengthened its liquidity through an ATM offering, ending the period with $9.47 million in cash and cash equivalents. GRI Bio remains a clinical-stage biopharmaceutical company with an accumulated deficit of $56.84 million and no significant revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.5-3.4
EPS (diluted, $ a share)$-0.69$-35.88

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

GRI Bio, Inc.: key numbers

Share price
$1.40Close, Nov 16
Market cap
$3.06M
Shares outstanding
2.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from GRI Bio, Inc.

All →
5:13 PM ET 8-K
Shareholder Meeting

GRI Bio Shareholder Meeting

GRI Bio held its 2026 Annual Meeting of Stockholders where shareholders elected W. Marc Hertz and David Szekeres as Class III directors and ratified WithumSmith+Brown, PC as the independent auditor. Stockholders also approved an amendment to the 2018 Equity Incentive Plan, increasing the share reserve by 546,529 shares and extending the evergreen provision to 2036.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.